Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common supplement lift depression and sharpen memory in seniors?

NCT ID NCT05257902

Symptom relief Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether choline alphoscerate, a dietary supplement, can improve depression, anxiety, and memory complaints in adults aged 60 and older with major depression. Participants take either the supplement or a placebo alongside their usual antidepressant medication. The study aims to see if adding choline alphoscerate leads to better outcomes than antidepressants alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dietary supplement called choline alphoscerate
What this could lead to
If it works, this could point toward a safe add-on treatment for depression and memory issues in older adults.
What could go wrong
This is a mid-sized trial, and the supplement may prove no better than placebo. Potential side effects are not yet well understood in this population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Aug 2022

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 60 years 2. Diagnosed as MDD under the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and confirmed with MINI-Depression 3. HAM-D ≥ 14 4. MMSE ≥ 20 5. Who had continuous subjective memory complaints more than 6 months before the period of screening 6. Who had taking antidepressants longer than 1 month in the period of screening Exclusion Criteria: 1. Diagnosed as schizophrenia, bipolar disorder, PTSD, OCD or other significant mental disorder under the criteria of DSM-5 (only the participants who had depressive disorder, sleep disorder, and the anxiety disorder are allowed to be included) 2. Who have medically unstable disease (only the participants, who have diabetes mellitus or hypertension under control with stable medication for 3 months could be included) 3. Diagnosed as dementia or mild cognitive impairment 4. Participants who are already taking choline alfoscerate within 4 weeks of period 5. Participants who have been taking medication of typical antipsychotics, mood stabilizer, cognitive enhancer including donepezil, rivastigamine, galantamine, and memantine within 1months. 6. Participants who had previous history of liver disease or renal disease 7. Participants who had allergic reaction to choline alfoscerate 8. Other specific condition, which could be inappropriate for the trial inclusion, under the judgement of the principal investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Major depression

Contacts and locations

Locations

  • Samsung Medical Center

    Seoul, Irwon-dong, Gangnam-gu, 135710, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.